Ausgewählte Studien

1. Diotallevi F., Paolinelli M., Radi G., Offidani A. Latest combination therapies in psoriasis: narrative review of the literature. Dermatol Ther. …Den ganzen Artikel lesen

Psoriasis has emerged as a systemic disease characterized by skin and joint manifestations as well as systemic inflammation and cardiovascular …Den ganzen Artikel lesen

Int J Womens Dermatol. 2020 Oct 10;7(3):314-318. doi: 10.1016/j.ijwd.2020.09.012. eCollection 2021 Jun. ABSTRACT BACKGROUND: Each year, 20,000 patients aged <10 years are diagnosed with psoriasis. Pediatric-onset psoriasis has many similarities to adult-onset disease, and previous studies suggest that the incidence might be increasing in both populations. OBJECTIVE: The challenges that arise when treating patients with psoriasis, especially those age <12 years, are

Ann Med. 2021 Dec;53(1):1727-1736. doi: 10.1080/07853890.2021.1986637. ABSTRACT OBJECTIVE: To critically analyse and define therapeutic objectives, response to treatment evaluation and related decisions in psoriasis. METHODS: Expert consensus meetings, a systematic and narrative reviews and a collaborative Delphi procedure were carried out. A steering committee from the Spanish Group of Psoriasis was established who based on the reviews generated a set of related statements. Subsequently, a grou

ZusammenfassungHintergrund und ZielsetzungFlexible Dosierungsschemata für Biologika bei der Behandlung von Psoriasis sind üblich, es liegen jedoch …Den ganzen Artikel lesen

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, Volume 21, Issue 11, Page 1387-1392, November 2023.Den ganzen Artikel lesen

J Dtsch Dermatol Ges. 2023 Nov;21(11):1387-1392. doi: 10.1111/ddg.15176_g. NO ABSTRACT PMID:37946641 | DOI:10.1111/ddg.15176_g Den ganzen Artikel lesen

J Eur Acad Dermatol Venereol. 2023 May 29. doi: 10.1111/jdv.19229. Online ahead of print. ABSTRACT BACKGROUND: Tildrakizumab (TIL) is an interleukin (IL)-23p19 inhibitor for the treatment of moderate-to-severe plaque psoriasis with long-term efficacy and safety demonstrated in phase III trials. Studies conducted in conditions closer to clinical practice are needed. OBJECTIVES: The TRIBUTE study (open-label, phase IV) assessed the efficacy and impact on Heath-Related Quality of Life (HRQoL) of TI

Exp Dermatol. 2021 Aug 25. doi: 10.1111/exd.14452. Online ahead of print. ABSTRACT Psoriasis is one of the most common chronic inflammatory skin diseases and at the same time a risk factor for cardiovascular disease. Interleukin-17A (IL-17A)-mediated inflammation in psoriasis may lead to vascular dysfunction. This study aimed at investigating whether anti-inflammatory treatment by tumor necrosis factor (TNF)-α blockade alters vascular function in psoriasis patients. A total of 11 patients with p

Full text linksCite Display options Display options Objectives: To assess the impact of low to moderate biomechanical stress on entheses in patients …Den ganzen Artikel lesen

Den ganzen Artikel lesen

Key words To the Editor: Patients with and dermatologists treating psoriasis usually strive for complete skin clearance, yet some patients prefer …Den ganzen Artikel lesen

Am J Clin Dermatol. 2022 Jul;23(4):547-559. doi: 10.1007/s40257-022-00702-2. Epub 2022 Jul 20. ABSTRACT BACKGROUND: The efficacy and safety of tralokinumab, a fully human monoclonal antibody that specifically neutralizes interleukin-13, plus topical corticosteroids (TCS) as needed were evaluated over 32 weeks in the phase III ECZTRA 3 trial. Significantly more tralokinumab- versus placebo-treated patients achieved the primary endpoints of Investigator's Global Assessment (IGA) score of 0/1 and 7

Clin Case Rep. 2022 Mar 20;10(3):e05647. doi: 10.1002/ccr3.5647. eCollection 2022 Mar. ABSTRACT Extrahepatic manifestations of chronic hepatitis C virus (HCV) infection frequently involve the skin. Here, we report the case of a woman, who experienced a psoriasis exacerbation on DAA treatment, which lead to psoriasis resolution upon HCV clearance under continued treatment with elbasvir/grazoprevir. PMID:35340644 | PMC:PMC8935055 | DOI:10.1002/ccr3.5647 Den ganzen Artikel lesen

Ther Adv Neurol Disord. 2021 Aug 23;14:17562864211035542. doi: 10.1177/17562864211035542. eCollection 2021. ABSTRACT The past decades have yielded major therapeutic advances in many autoimmune conditions - such as multiple sclerosis (MS) - and thus ushered in a new era of more targeted and increasingly potent immunotherapies. Yet this growing arsenal of therapeutic immune interventions has also rendered therapy much more challenging for the attending physician, especially when treating patients

Autoimmun Rev. 2023 Mar 15;22(5):103312. doi: 10.1016/j.autrev.2023.103312. Online ahead of print. ABSTRACT More than 10 disease-modifying therapies (DMT) are approved by the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) for the treatment of multiple sclerosis (MS) and new therapeutic options are on the horizon. Due to different underlying therapeutic mechanisms, a more individualized selection of DMTs in MS is possible, taking into account the patient's current s

To the Editor: Psoriasis affects nails in approximately 15% to 50% of patients, whereas isolated involvement is observed in 5% to 10% of …Den ganzen Artikel lesen

Am J Clin Dermatol. 2024 Mar;25(2):333-342. doi: 10.1007/s40257-024-00845-4. Epub 2024 Jan 24. ABSTRACT BACKGROUND: Tuberculosis has a major global impact. Immunocompetent hosts usually control this disease, resulting in an asymptomatic latent tuberculosis infection (LTBI). Because TNF inhibitors increase the risk of tuberculosis reactivation, current guidelines recommend tuberculosis screening before starting any biologic drug, and chemoprophylaxis if LTBI is diagnosed. Available evidence from

Dermatologie (Heidelb). 2024 Mar 7. doi: 10.1007/s00105-024-05310-1. Online ahead of print. ABSTRACT Psoriasis is a chronic inflammatory systemic disease that requires optimal long-term management due to its high prevalence in the population and the numerous comorbidities that severely impair quality of life. A variety of treatment options are now available. In addition to objective skin findings and a specific location such as nails or genital area, the presence of psoriatic arthritis and other

Hautarzt. 2021 Aug 20:1-8. doi: 10.1007/s00105-021-04871-9. Online ahead of print. ABSTRACT BACKGROUND: Moderate to severe plaque psoriasis can be treated effectively with immunomodulating biologicals such as the interleukin-17A inhibitor secukinumab. In practice, however, questions often arise as to how to proceed in special situations, such as infections, comorbidity, pregnancy, or surgery. OBJECTIVES: To address frequent questions about the treatment of plaque psoriasis with secukinumab in a

Internist (Berl). 2022 Feb;63(2):135-142. doi: 10.1007/s00108-021-01248-x. Epub 2022 Jan 14. ABSTRACT Biologics are an integral part of modern strategies for treatment of rheumatoid arthritis (RA) and spondylarthritis (SpA), including psoriatic arthritis (PsA). Biologics are biotechnologically produced proteins that have inhibiting effects on humoral and cellular components of rheumatic inflammation. Substance classes used in rheumatology are tumor necrosis factor (TNF)-alpha, interleukin (IL)-1

Dermatol Ther (Heidelb). 2024 Mar 5. doi: 10.1007/s13555-024-01109-z. Online ahead of print. ABSTRACT INTRODUCTION: Limited information exists on the epidemiology, treatment, and burden of palmoplantar pustulosis (PPP) and defining the optimal course of treatment remains challenging without approved targeted treatments in most countries. Here, we describe the clinical and demographic characteristics, treatments received, and negative health outcomes experienced among patients with PPP in the Uni

Rheumatol Ther. 2021 Aug 24. doi: 10.1007/s40744-021-00347-3. Online ahead of print. ABSTRACT BACKGROUND: Uncontrolled inflammatory disease activity can impact pregnancy outcomes and the health of the mother and child. This retrospective claims database analysis assessed treatment patterns before, during, and after pregnancy among women with inflammatory rheumatic disease (IRD; axial spondyloarthritis [axSpA], psoriatic arthritis [PsA], and rheumatoid arthritis [RA]) or psoriasis (PSO) in German

Den ganzen Artikel lesen

Den ganzen Artikel lesen